Inside Time: A Fresh Idea from Cathie Wood

Inside Time: A Fresh Idea from Cathie Wood The original investment logic of the scandalous trader periodically brings huge profits to the ARK Invest ETF (for example, during a pandemic). But in last year's bear market, her strategy was wildly ineffective. What does the lady suggest now?Cathie has always preferred disaster companies, and even in the most difficult periods she did not refuse this tactic. Recently, she again decided to buy and her choice again surprised investors. Wood found a very inexpensive stock (about $7.30-$7.50) with serious upside potential.Adaptive Biotechnologies (NYSE: ADPT)This cutting-edge biotechnology company is innovating in immune diagnostics and therapeutics and is in an active phase of commercial development. Adaptive Biotechnologies reaffirmed its 2023 revenue expectations in the range of $205 million to $215 million. The company's first-quarter revenue was $37.6 million, up $0.69 million from guidance.At the same time, earnings per share of $0.40 turned out to be worse than expected, which slightly unnerves investors, but this indicator is not critical for Cathie's strategy.Wood purchased 558,196 ADPT shares through her ARK Genomic Revolution ETF (NYSE: ARKG) in May alone. The total number of ADPT shares in this fund has now reached 9,554,319, representing a market value of over $62.58 million.At the moment, a drawdown of 15-20% since the beginning of the year has already been eliminated. The "STRONG BUY" recommendation is confirmed by large investment funds: ADPT shares are considered an excellent medium-term buy option for those who are late to join the NVIDIA (NASDAQ: NVDA) hype.First target zone: $10.50; potential until the end of the year - $15.Profits to yall!#ForexChief #AdaptiveBiotechnologies #GenomicRevolution #forexnews #stocks #worldnews #Market